Update on tamper-resistant drug formulations

Drug and Alcohol Dependence

Volumn 130, Issue 1-3, 2013, Pages 13-23

  Romach, M K ^a   Schoedel, K A ^b   Sellers, E M ^a,c  

^a DL Global Partners Inc   (Canada)

^b SYNEOS HEALTH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abuse deterrent; Abuse liability; Drug formulations; Opioid; Tamper resistant; Tampering

Indexed keywords

BUPRENORPHINE; DEXAMPHETAMINE; HYDROCODONE; MACROGOL; MORPHINE; NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PRESCRIPTION DRUG; PRODRUG;

DRUG ABUSE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TABLET FORMULATION; UNITED STATES;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; PRODRUGS;

EID: 84877026031     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.028     Document Type: Review

References (77)

1. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
2. Amorim Cde M., Couto A.G., Netz D.J., de Freitas R.A., Bresolin T.M. Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan. Nanomedicine 2010, 6:745-752.
3. ® opioids have low abuse and tampering attractiveness relative to marketed opioids. J. Pain 2009, 10:S60.
4. Annas G.J. Standard of care-in sickness and in health and in emergencies. N. Engl. J. Med. 2010, 362:2126-2131.
5. Armstrong S.C., Cozza K.L. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003, 44:515-520.
6. Barkin R.L., Iasco A.M., Barkin S.J. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. Weiner's Pain Management: A Practical Guide for Clinicians 2006, Taylor & Francis, New York, NY. 7th ed. M.V. Boswell, B.E. Cole (Eds.).
7. Bartholomäus J., Arkenau-Maric E., Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin. Drug Deliv. 2012, 9:879-891.
8. Benedek I.H., Jobes J., Xiang Q., Fiske W.D. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des. Dev. Ther. 2011, 5:455-463.
9. Berner T., Thomson H., Hartry A., Puenpatom R.A., Ben-Joseph R., Szeinbach S.L. A comparison of daily average consumption of oxycodone controlled release (oxyContin CR) and oxymorphone extended release (Opana ER) in patients with low back pain. P&T 2011, 36:139-144.
10. Blondell R.D., Ashrafioun L., Dambra C.M., Foschio E.M., Zielinski A.L., Salcedo D.M. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J. Addict. Med. 2010, 4:140-146.
11. Bruce R.D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F.L. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse 2009, 35:68-72.
12. Butler S.F., Benoit C., Budman S.H., Fernandez K.C., McCormick C., Venuti S.W., Katz N. Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct. J. 2006, 3:5.
13. Butler S.F., Black R., Grimes Serrano J.M., Folensbee L., Chang A., Katz N. Estimating attractiveness for abuse of a not-yet-marketed " abuse-deterrent" prescription opioid formulation. Pain Med. 2010, 11:81-91.
14. Butler S.F., Black R.A., Cassidy T.A., Dailey T.M., Budman S.H. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct. J. 2011, 8:29.
15. Cassidy, T., Coplan, P., Black, R.A., Chilcoat, H., Budman, S.H., Butler, S. Initial Findings on Abuse Rates and Routes of Administration Following Introduction of Reformulated OxyContin® in a Sentinel Surveillance System of Patients in Substance Use Treatment. Presented at: PAINWeek. Las Vegas, NV, September 7-11, 2011.
16. CBS New York Online, 2011. Nassau County executive: abuse of painkiller Opana is growing-Docs: it's replacing OxyContin and is twice as powerful. Available at: (accessed 25.10.11). http://newyork.cbslocal.com/2011/05/09/nassau-county-executive-issues-public-health-alert-concerning-opana/.
17. Chou R., Fanciullo G.J., Fine P.G., Adler J.A., Ballantyne J.C., Davies P., Donovan M.I., Fishbain D.A., Foley K.M., Fudin J., Gilson A.M., Kelter A., Mauskop A., O'Connor P.G., Passik S.D., Pasternak G.W., Portenoy R.K., Rich B.A., Roberts R.G., Todd K.H., Miaskowski C. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 2009, 10:113-130.
18. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. N. Engl. J. Med. 2012, 367:187-189.
19. Cicero T.J., Inciardi J.A., Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J. Pain 2005, 6:662-672.
20. Comer S.D., Ashworth J.B., Sullivan M.A., Vosburg S.K., Saccone P.A., Foltin R.W. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J. Opioid Manag. 2009, 5:203-212.
21. Comer S.D., Sullivan M.A., Vosburg S.K., Manubay J., Amass L., Cooper Z.D., Saccone P., Kleber H.D. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010, 105:709-718.
22. Department of Health and Human Services, 2011. Food and Drug Administration. Sec. 300.50 Fixed-combination Prescription Drugs for Humans), Code of Federal Regulations [Title 21, Volume 5].
23. Drug Abuse Warning Network, 2010. US Department of Health and Human Services. Available at: (accessed 02.06.10). https://dawninfo.samhsa.gov/default.asp.
24. DrugWatch, 2011. Pain drug Embeda recalled due to defect in formula. Available at: (accessed 03.10.11). http://www.drugwatch.com/news/2011/03/17/pain-drug-embeda-recalled-due-defect-formula/.
25. Egalet, 2011. Corporate Website. Available at: , (accessed 04.12.11). http://www.egalet.com/.
26. Endo Pharmaceuticals, Inc., 2012. Endo announces FDA approval of a new formulation of Opana® ER designed to be crush resistant. Available at: http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201112120800PR_NEWS_USPRX____PH20693&feedID=600&press_symbol=98702, (accessed 25.01.12).
27. Engel K., Reuter J., Seiler C., Schulte Monting J., Jakob T., Schempp C.M. Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. J. Eur. Acad. Dermatol. Venereol. 2008, 22:447-450.
28. Goodnough A., Zezima K. Drug is harder to abuse, but users persevere. New York Times 2011, 15(June):2011.
29. Greenberg M.D. Medical malpractice and new devices: defining an elusive standard of care. Health Matrix Clevel 2009, 19:423-445.
30. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 2004, 43:879-923.
31. Grudzinskas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C.E., Mansbach R.S., McCormick C.G., Schnoll S.H., Strain E.C., Wright C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006, 83:S77-S82.
32. Haahr, A.M., Lyhne-Iversen, S., Ridderberg, S., Nilsson, M., Hemmingsen, P.H., 2007. Drug Abuse Resistant, Controlled Release, Using Egalet® Dosage Units. Presented at: 34th Annual Meeting & Exposition of the Controlled Release Society. Long Beach, CA, July 7-11, 2007.
33. Inturrisi C.E., Schultz M., Shin S., Umans J.G., Angel L., Simon E.J. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983, 33(Suppl. 1):773-776.
34. Jang D.H., Rohe J.C., Hoffman R.S., Nelson L.S. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann. Emerg. Med. 2010, 55:303-304.
35. Jasinski D.R., Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J. Psychopharmacol. 2009, 23:419-427.
36. Jasinski D.R., Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J. Psychopharmacol. 2009, 23:410-418.
37. Jayawant S.S., Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther. Clin. Risk Manag. 2005, 1:77-82.
38. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012, 120:190-195.
39. Jones J.D., Sullivan M.A., Manubay J., Vosburg S.K., Comer S.D. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology 2011, 36:411-422.
40. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream?. Curr. Rheumatol. Rep. 2008, 10:11-18.
41. Kollins S.H., Youcha S., Lasser R., Thase M.E. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innov. Clin. Neurosci. 2011, 8:28-32.
42. Larance B., Degenhardt L., Lintzeris N., Bell J., Winstock A., Dietze P., Mattick R., Ali R., Horyniak D. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011, 118:265-273.
43. Loder E. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalalgia 2006, 26:89-97.
44. Lowe D.O., Knowles S.R., Weber E.A., Railton C.J., Shear N.H. Povidone-iodine-induced burn: case report and review of the literature. Pharmacotherapy 2006, 26:1641-1645.
45. Lowenstein O., Leyendecker P., Lux E.A., Blagden M., Simpson K.H., Hopp M., Bosse B., Reimer K. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin. Pharmacol. 2010, 10:12.
46. McColl S., Sellers E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 2006, 83(Suppl. 1):S52-S62.
47. Meissner W., Leyendecker P., Mueller-Lissner S., Nadstawek J., Hopp M., Ruckes C., Wirz S., Fleischer W., Reimer K. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur. J. Pain 2009, 13:56-64.
48. Mercadante S., Ferrera P., Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support. Care Cancer 2011, 19:1471-1472.
49. Merrigan, T., Friedmann, N., Butera, P., Klutzaritz, V., Gilmore, D., Webster, L., 2008. Abuse-resistant, Controlled-release Oxycodone Treats Chronic Pain. Presented at: American Academy of Pain Medicine 24th Annual Meeting. Orlando, FL, February 12-16, 2008.
50. Middleton L.S., Nuzzo P.A., Lofwall M.R., Moody D.E., Walsh S.L. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011, 106:1460-1473.
51. National Opioid Use Guideline Group, 2010. Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain. McMaster University. Available at: (accessed 12.06.12). http://nationalpaincentre.mcmaster.ca/opioid/.
52. OXECTA® (Oxycodone HCl, USP) Full Prescribing Information 2011, King Pharmaceuticals, Bristol, TN.
53. OxyContin® (Oxycodone HCl Controlled-release Tablets) Full Prescribing Information 2011, Purdue Pharma L.P., Stamford, CT.
54. Passik S.D., Hays L., Eisner N., Kirsh K.L. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J. Pain Palliat. Care Pharmacother. 2006, 20:5-13.
55. Pfizer Inc, Pain Therapeutics Inc., 2011. FDA complete response letter received for Remoxy [press release]. Available at: (accessed 24.6.11). http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp.
56. Pisgah Forest, 2011. Abuse deterrent hydrocodone/acetaminophen leads NDA pipeline. Available at: (accessed 02.09.11). http://www.akelapharma.com/modules.php?op=modload%26name=News%26file=article%26sid=67.
57. Preston K.L., Bigelow G.E. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J. Pharmacol. Exp. Ther. 2000, 295:114-124.
58. Proeschel P.A., Morneburg T. Task-dependence of activity/bite-force relations and its impact on estimation of chewing force from EMG. J. Dent. Res. 2002, 81:464-468.
59. Purdue Pharma L.P., 2012. Dear healthcare professional. Available at: (accessed 22.03.12). http://www.purduepharma.com/pdfs/dearHCPletter.pdf.
60. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 1993, 33:81-86.
61. Rolleri R.L., Faulknor J., Schoedel K.A., Pixton G.C., Chen N., Bass A., Sellers E.M. Intranasal Abuse Potential of Immediate-release Oxycodone (Acurox®; IROA) Formulated to Deter Abuse. College on Problems of Drug Dependence 73rd Annual Scientific Meeting 2011.
62. Ruan X., Chen T., Gudin J., Couch J.P., Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J. Opioid Manag. 2010, 6:300-303.
63. Sandner-Kiesling A., Leyendecker P., Hopp M., Tarau L., Lejcko J., Meissner W., Sevcik P., Hakl M., Hrib R., Uhl R., Durr H., Reimer K. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int. J. Clin. Pract. 2010, 64:763-774.
64. Schoedel K.A., McMorn S., Chakraborty B., Potts S.L., Zerbe K., Sellers E.M. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J. Opioid Manag. 2011, 7:179-192.
65. Simpson K., Leyendecker P., Hopp M., Muller-Lissner S., Lowenstein O., De Andres J., Troy Ferrarons J., Bosse B., Krain B., Nichols T., Kremers W., Reimer K. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr. Med. Res. Opin. 2008, 24:3503-3512.
66. Slevin K.A., Ashburn M.A. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J. Opioid Manag. 2011, 7:109-115.
67. Substance Abuse and Mental Health Services Administration, 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Available at: (accessed 03.10.11). http://www.oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf.
68. Ultram ER® (Tramadol Hydrochloride) Full Prescribing Information 2009, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ.
69. US Department of Justice, Drug Alert Watch Oxymorphone Abuse: A Growing Threat Nationwide 2011, US Department of Justice, Johnstown, PA, May 19. EWS Report 000011.
70. US Food and Drug Administration. Code of Federal Regulations, 2012. Title 21 - Food and Drugs. Subchapter D - Drugs for human use. Part 314 - Applications for FDA approval to market a new drug. Subpart D - FDA action on applications and abbreviated applications. § 314.161 Determination of reasons for voluntary withdrawal of a listed drug. Available at: (accessed 22.08.12). http://www.gpo.gov/fdsys/pkg/CFR-2006-title21-vol5/xml/CFR-2006-title21-vol5-sec314-161.xml.
71. US Food and Drug Administration, 2011. FDA approves new formulation for OxyContin [press release]. Available at: (accessed 14.02.11). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm.
72. US Food and Drug Administration Guidance for Industry: Assessment of Abuse Potential of Drugs 2010, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
73. Vicknasingam B., Mazlan M., Schottenfeld R.S., Chawarski M.C. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010, 111:44-49.
74. Vosburg S.K., Jones J.D., Manubay J.M., Ashworth J.B., Benedek I.H., Comer S.D. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012, (Epub ahead of print).
75. Walsh S.L., Nuzzo P.A., Lofwall M.R., Holtman J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008, 98:191-202.
76. Watkins P.B., Kaplowitz N., Slattery J.T., Colonese C.R., Colucci S.V., Stewart P.W., Harris S.C. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87-93.
77. Zacny J.P., Lichtor S.A. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacol. (Berl.) 2008, 196:105-116.